Adipotide: Dosing Protocols

Research Dosing Disclaimer#

Adipotide (FTPP) is an experimental research compound that has never been tested in humans. No approved dosing guidelines exist for this peptide. The information below is derived exclusively from preclinical animal studies and is provided for educational and research reference purposes only. These animal doses should not be extrapolated to human use.

Preclinical Dosing Data#

Mouse Studies#

In the foundational study by Kolonin et al. (2004), adipotide was administered at 1 mg/kg/day via intraperitoneal injection to diet-induced obese mice for 4 weeks. This dose was sufficient to produce approximately 30% body weight reduction through selective ablation of white adipose tissue vasculature.

Kim, Woods, and Seeley (2010) used a similar dosing regimen of 1 mg/kg/day intraperitoneally in mice on a high-fat diet, achieving complete reversal of obesity within 27 days. The consistency of dosing across mouse studies suggests this represents the effective dose range in this species.

The 2012 study by Kim et al. examining weight-independent metabolic effects also employed the 1 mg/kg/day intraperitoneal dosing protocol, confirming that this dose level produces both the expected fat reduction and the metabolic improvements.

Primate Studies#

The Barnhart et al. (2011) primate study used subcutaneous injection at doses ranging from 0.5 to 1.0 mg/kg/day for 28 days in spontaneously obese rhesus monkeys. The subcutaneous route was chosen over intraperitoneal for primate studies as it better represents potential clinical administration. At these doses, significant fat reduction and metabolic improvement were observed, but dose-dependent renal toxicity was also noted.

Administration Routes#

The intraperitoneal route is standard for mouse pharmacology studies but is not used clinically. The subcutaneous route used in the primate study is more relevant to potential clinical translation, though no human studies have been conducted.

Dose-Response Relationship#

Limited dose-response data are available from published studies. The primate study used a narrow dose range (0.5-1.0 mg/kg), and a clear dose-response relationship for efficacy was not extensively characterized. However, the renal toxicity appeared to be dose-dependent, with higher doses producing more pronounced tubular effects.

The minimum effective dose has not been formally established in any species. The 1 mg/kg/day dose used across mouse studies appears to produce robust effects, but whether lower doses could achieve therapeutic benefit with reduced toxicity remains unexplored in the published literature.

Treatment Duration Considerations#

In mouse studies, significant weight loss was observed within the first week of treatment, with continued reduction over the 4-week treatment period. In the primate study, fat reduction progressed throughout the 28-day treatment period and continued to some degree during the recovery period, likely reflecting the ongoing clearance of damaged adipose tissue after treatment cessation.

The optimal treatment duration has not been established. The irreversible nature of the vascular destruction and adipose tissue ablation suggests that prolonged treatment may not be necessary to achieve lasting fat reduction, though the potential for adipose tissue regeneration over longer time frames has not been studied.

Storage and Handling#

Adipotide is a peptide compound that requires standard cold-chain storage. The lyophilized form should be stored at -20 degrees Celsius or below. Once reconstituted in sterile saline, solutions should be used promptly or stored at 2-8 degrees Celsius for short-term use only. The disulfide bond in the cyclic homing domain is sensitive to reducing conditions, so reconstitution buffers should not contain reducing agents such as DTT or beta-mercaptoethanol.

Protection from light is recommended, and repeated freeze-thaw cycles should be avoided as they may compromise the structural integrity of the cyclic homing domain and reduce the compound's targeting efficacy.

Safety Monitoring in Research Settings#

Given the known renal toxicity observed in primate studies, any research use of adipotide should include monitoring of renal function parameters. In the primate study, renal effects were assessed by monitoring serum creatinine, blood urea nitrogen, and urinalysis for markers of tubular injury. The renal effects were described as predictable, dose-dependent, and largely reversible upon treatment cessation, but this observation was limited to the specific dose range and duration tested.

Human Equivalent Dose Considerations#

While formal allometric scaling has not been published for adipotide, standard body surface area conversion from the mouse dose of 1 mg/kg would yield a considerably lower estimated human equivalent dose. However, such calculations are purely theoretical, as no pharmacokinetic data in humans exist, and the renal toxicity observed in primates suggests that the therapeutic index may be narrow. Any consideration of human dosing would require extensive preclinical toxicology and pharmacokinetic characterization that has not yet been conducted.

Related Reading#

• Adipotide overview and research guide
• Adipotide side effects profile
• Adipotide research evidence